Heart failureSenescenceSTAT1STINGHeart failure with preserved ejection fraction (HFpEF) is a mortal clinical syndrome without effective therapies. Empagliflozin (EMPA) improves cardiovascular outcomes in HFpEF patients, but the underlying mechanism remains elusive. Here, mice were fed a high-fat diet (...
has also been approved in the EU and USA for the treatment of all adults with symptomatic chronic heart failure (CHF), regardless of their left ventricular ejection fraction (LVEF). In pivotal phase III trials in ambulant patients with
Dysregulated cellular iron uptake/availability may be a shared mechanism in myocardial structural/functional impairment, reduced exercise capacity, and restricted haematopoiesis in heart failure, which are worse in patients with anaemia, and improve with empagliflozin. Empagliflozin increases MIC and decreases...
CSA = cross-sectional area; other abbreviations as in Figure 1. Molecular studies To assess the mechanism in which early active energy-dependent relaxation was improved with empagliflozin therapy, we assessed a range of proteins involved in calcium handling and the hypertrophic response. There was ...
with type 1 diabetes as it may increase the risk of diabetic ketoacidosis in these patients. It is not for use to improve glycemic control in adults with type 2 diabetes with an eGFR <30 mL/min/1.73 m2as it is likely to be ineffective in this setting based upo...
Inhibition of the sodium-glucose cotransporter-2 (SGLT2i) improves outcomes in patients with heart failure (HF) and reduced ejection fraction (HFrEF), but the mechanism by which they improve outcomes remains unclear. Objectives This study aimed to investigate the effects of sodium-glucose cotransport...
JARDIANCE is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m². JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action. ...
The effect of empagliflozin on right ventricular function in heart failure patients with reduced ejection fraction: analysis from the randomized empire hf ... mechanism to the cardio-protective effects of sodium-glucose-transporter-2 (SGLT2) inhibitors in patients with heart failure and reduced ...
Several other questions remained unanswered, such as the mechanism of action. An animal model of both hypertension and diabetes might have more utility than either condition alone. We generated a novel rodent model for heart failure by mating rats with type 2 diabetes and hypertension11,12. Heart...
Although it was not measured in the current study, the effect of empagliflozin on the abnormal ventricular electrophysiological profile exists in cardiac hypertrophy and failure 22, 23, 24, 25 may offer insight into the mechanism of action and would therefore be an area to explore in future studi...